Fintel reports that on March 13, 2025, Citigroup initiated coverage of Avidity Biosciences (NasdaqGM:RNA) with a Buy ...

Citi initiated coverage of Avidity Biosciences (RNA) with a Buy rating and $70 price target Healthcare policy remains a key biopharma sector ...

BMO Capital initiated coverage of Avidity Biosciences (RNA) with an Outperform rating and $72 price target Avidity’s pipeline includes ...

Avidity Biosciences specializes in RNA-based therapies using Antibody-oligonucleotide conjugates to deliver drugs directly to muscle and heart cells. Learn more on RNA stock here.

Scotiabank began coverage on shares of Avidity Biosciences (NASDAQ:RNA – Free Report) in a report issued on Friday morning, ...

Del-zota produced statistically significant increases in exon skipping and dystrophin levels in EXPLORE44, a Phase 1/2 study in patients with DMD44 (oral presentation) Aravindhan Veerapandiyan, MD ...

Fintel reports that on March 12, 2025, BMO Capital initiated coverage of Avidity Biosciences (NasdaqGM:RNA) with a Outperform recommendation. As of March 5, 2025, the average one-year price target ...

NASDAQ RNA opened at $30.04 on Monday. The firm has a market capitalization of $3.61 billion, a P/E ratio of -10.43 and a beta of 1.02. Avidity Biosciences has a 1-year low of $20.80 and a 1-year ...

Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics ...

BMO Capital Markets initiated coverage on Dyne Therapeutics, Inc. (NASDAQ:DYN), focused on developing therapies for ...

Building on success across its three clinical programs, Avidity is leading in rare neuromuscular diseases with a strong balance sheet to execute on a transformational 2025 Major milestones ...

Aravindhan Veerapandiyan, MD, Associate Professor of Pediatrics, University of Arkansas for Medical Sciences and Arkansas Children's Hospital and ...